Abstract 16655: Liver Fibrosis Severity is Associated with Congestive Heart Failure in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease
Abstract
Background - Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disorder. Although cardiovascular disease is the leading cause of mortality in MASLD, the relationship between liver fibrosis severity and congestive heart failure (CHF) at the population level remains ill-defined. We evaluated the association between vibration-controlled transient elastography (VCTE)-derived liver stiffness and prevalent CHF among U.S. adults with MASLD. Methods - We performed a cross-sectional analysis of the National Health and Nutrition Examination Survey. MASLD was defined by hepatic steatosis (controlled attenuation parameter ≥274 dB/m) plus ≥1 cardiometabolic risk factor after exclusion of competing liver disease and significant alcohol use. Liver stiffness measurement (LSM) was analyzed continuously, by quartiles, and as advanced fibrosis (LSM ≥9.7 kPa). The primary outcome was self-reported CHF. Weighted multivariable logistic regression accounting for the complex NHANES design was performed. Results - Among 2,019 adults with MASLD, weighted CHF prevalence was 3.3% (n=88). Participants with CHF were older (68.0±9.4 vs 55.5±15.6 years; p<0.001), had higher body mass index (35.5±7.5 vs 32.9±7.0 kg/m 2 ; p=0.002), and greater liver stiffness (8.58±6.19 vs 6.56±4.90 kPa; p=0.003). Advanced fibrosis was more prevalent among participants with CHF versus those without CHF (30.0% vs 9.6%; p<0.001). In unadjusted bivariate analysis (Model-1), advanced fibrosis was associated with higher odds of CHF (OR 3.86; p<0.001). After adjustment for age, sex, and race/ethnicity (Model-2), advanced fibrosis remained significantly associated with CHF (OR 3.79; 95% CI 2.00-7.18; p<0.001). Each unit increase in log-transformed LSM was associated with increased odds of CHF (OR 3.20; 95% CI 2.00-5.12; p<0.001). Compared with the lowest liver stiffness quartile, participants in the third and fourth quartiles demonstrated significantly higher odds of CHF (Q3: OR 4.24; 95% CI 1.45-12.4; p=0.012; Q4: OR 4.60; 95% CI 1.90-11.1; p=0.002). Additional adjustment for obesity, diabetes, and hypertension (Model-3) attenuated the continuous association between LSM and CHF (OR 1.93; 95% CI 0.82-4.54; p=0.12). Conclusions - Among U.S. adults with MASLD, advanced liver fibrosis is strongly associated with prevalent CHF. Individuals with advanced fibrosis had nearly four-fold greater odds of heart failure, showing that liver fibrosis may identify a high-risk cardiometabolic phenotype. The attenuation of this association after adjustment for metabolic comorbidities suggests shared cardiometabolic pathways may substantially mediate the liver-heart axis.